Skip to content

Download our latest eBook on lung airway epithelial cell and fibroblast models

Illustration of lungs

Lung Airway Models

Primary and iPSC models that mimic the function and cellular interactions in the lung

Models available
  • Primary Human Lung Fibroblasts
  • Primary Small Airway Epithelial Cell Model
  • In development – alveolar model
Measurable outputs
  • Extra cellular matrix (ECM) deposition
  • Cell number/Proliferation
  • Deposition of Collagen I and III
  • Detection of α-SMA
  • Cell viability and compound toxicity
  • TransEpithelial Electrical Resistance (TEER)
  • Evaluation of anti-fibrotic properties of new compounds
  • Respiratory disease modelling
  • Lung toxicity
  • Human

Our Models

Human Lung Fibroblasts

Our Fibroblast-to-Myofibroblast Transition (FMT) assay is robust and validated. The 384-well format allows rapid evaluation of multiple compounds and conditions using imaging outputs.

More Information
Human lung fibroblasts stimulated with TGF-β1 for 72hours and immunostained to detect total collagen I (pink) and alpha-smooth muscle actin(α-SMA) (green) as a measure of matrix production and fibroblast activation respectively.

Human Small Airway Epithelial Cell Model

A robust, physiologically relevant lung air-liquid interface epithelial model to enable scientific research and drug discovery

More Information
Small Airway Epithelial Cells immunostained to detect for Basal cell (KRT5), Club cell (CC10/SCGB1A1) and Junctional protein (ZO1) markers

Benefits of our model


High-throughput FMT assay


Models that mimic in vivo function


Three donors available per study

Working with us

Timely service

Our service timelines are short due to the efficiency of our assay. We can provide multiple data points on a single plate in as little as 2 months. Our FMT assay evaluates both collagen I and III as well as α-smooth muscle actin.

Model validation

Our lung tissue model is well-characterised and rigorously validated to ensure the generation of robust and predictive data. Our clients also value our scientific expertise in the analysis and interpretation of data.

How we support our clients

By providing predictive data, we give our clients confidence in their key decision processes using our lung model and our Lung Fibroblast-to-Myofibroblast Transition (FMT) assay service.

Our expertise

Our team is experienced in assay development for drugs targeting the lung with specific knowledge of fibrosis. By combining this knowledge with primary and iPSC cell technology, they have developed assays that can help our customers screen, optimise and select candidates for combating fibrosis.

Get our latest updates straight to your inbox